A five‐alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats

BACKGROUND The objective of this study was to elucidate the prophylactic effects of 5‐alpha reductase inhibitor (e.g., finasteride) and a pure antiandrogen (e.g., casodex) on rat prostate carcinogenesis and to determine whether latent prostate carcinoma can be prevented to develop to clinically sign...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 1998-02, Vol.82 (3), p.531-537
Hauptverfasser: Tsukamoto, Sadamu, Akaza, Hideyuki, Onozawa, Mizuki, Shirai, Tomoyuki, Ideyama, Yukitaka
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND The objective of this study was to elucidate the prophylactic effects of 5‐alpha reductase inhibitor (e.g., finasteride) and a pure antiandrogen (e.g., casodex) on rat prostate carcinogenesis and to determine whether latent prostate carcinoma can be prevented to develop to clinically significant cancer by use of these drugs. METHODS F344 rats were subcutaneously administered 3,2'‐dimethyl‐4‐aminobiphenyl (DMAB) for the first 20 weeks and testosterone propionate throughout the 60‐week study. Finasteride (5 mg/kg and 15 mg/kg, 2 times per week) and casodex (15 mg/kg, 30 mg/kg, and 60 mg/kg, 3 times per week) were administered orally during the last 40 weeks of the study. Tumors were classified as visible prostate carcinoma when they could be recognized with the naked eye and as microscopic prostate carcinoma when detectable only with a microscope. RESULTS The incidence of visible prostate carcinoma was 51% (18 of 35 rats) in the positive control group, whereas it was 40% (4 of 10 rats) in the finasteride 5 mg/kg group, 16.7% (2 of 12 rats, P = 0.0091) in the finasteride 15 mg/kg group, 20% (4 of 20 rats, P = 0.05) in the casodex 15 mg/kg group, 14.3% (3 of 21 rats, P = 0.0008) in the casodex 30 mg/kg group, and 0% (0 of 11 rats, P = 0.0002) in the casodex 60 mg/kg group. On the other hand, when visible carcinomas and microscopic carcinomas were handled together, only casodex 60 mg/kg significantly inhibited the carcinogenesis rate. CONCLUSIONS Finasteride achieved dose‐dependent inhibition of macroscopic rat prostate carcinogenesis, and casodex also inhibited macroscopic prostate carcinogenesis. However, both drugs showed insufficient prevention of carcinogenesis at the microscopic level. These findings indicate that, in clinical medicine as well, such drugs may also be able to prevent the progression of latent prostate carcinoma to life‐threatening disease. Cancer 1998;82:531‐7. © 1998 American Cancer Society. Finasteride and casodex achieved inhibition of rat prostate carcinogenesis at the macroscopic level but showed insufficient inhibition at the microscopic level. The findings of this study indicate that, in clinical medicine as well, such drugs may also be able to prevent the progression of latent prostate carcinoma to life‐threatening disease.
ISSN:0008-543X
1097-0142
DOI:10.1002/(SICI)1097-0142(19980201)82:3<531::AID-CNCR15>3.0.CO;2-2